Cowen analyst Phil Nadeau downgraded Frequency Therapeutics (NASDAQ: FREQ) from Outperform to Market Perform.The analyst commented, "FX-322's Ph IIb in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE